Garching / Munich, January 5, 2022 - ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that CEO, Steffen Schuster will present a corporate overview and update at the virtual 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 10.30am ET (4.30pm CET).
- End -
About ITM Isotope Technologies Munich SE
ITM, a radiopharmaceutical biotech company, is dedicated to providing the most precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians and our partners through excellence in development, production and global supply. With patient benefit as the driving principle for all we do, ITM is advancing a broad pipeline, including two phase III studies, combining its high-quality radioisotopes with targeting molecules to develop precision oncology treatments. ITM is leveraging its leadership and nearly two decades of radiopharma expertise combined with its worldwide network to enable nuclear medicine to reach its full potential for helping patients live longer and better.
For more information please visit: www.itm-radiopharma.com.
ITM Contact
Corporate Contact
Julia Hofmann / Susanne Karlsson
Corporate Communications
Phone: +49 89 329 8986 1502
Email: communications(at)itm-radiopharma.com
Investor Contact
Ben Orzelek
Investor Relations
Phone: +49 89 329 8986 1009
Email: Ben.Orzelek(at)itm-radiopharma.com
ITM Media Requests
Trophic Communications
Stephanie May or Valeria Fisher
Phone: +49 171 185 56 82
Email: itm(at)trophic.eu
